[go: up one dir, main page]

AP2013007070A0 - Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders - Google Patents

Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders

Info

Publication number
AP2013007070A0
AP2013007070A0 AP2013007070A AP2013007070A AP2013007070A0 AP 2013007070 A0 AP2013007070 A0 AP 2013007070A0 AP 2013007070 A AP2013007070 A AP 2013007070A AP 2013007070 A AP2013007070 A AP 2013007070A AP 2013007070 A0 AP2013007070 A0 AP 2013007070A0
Authority
AP
ARIPO
Prior art keywords
triazines
imidazo
treatment
neurological disorders
neurological
Prior art date
Application number
AP2013007070A
Other languages
English (en)
Inventor
Eddie Yang
John Michael Humphrey
Christopher John Helal
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45755439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2013007070(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AP2013007070A0 publication Critical patent/AP2013007070A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2013007070A 2011-02-23 2012-02-09 Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders AP2013007070A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161445617P 2011-02-23 2011-02-23
PCT/IB2012/050589 WO2012114222A1 (fr) 2011-02-23 2012-02-09 Imidazo[5,1-f][1,2,4] triazines pour traiter les troubles neurologiques

Publications (1)

Publication Number Publication Date
AP2013007070A0 true AP2013007070A0 (en) 2013-08-31

Family

ID=45755439

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013007070A AP2013007070A0 (en) 2011-02-23 2012-02-09 Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders

Country Status (31)

Country Link
US (2) US8598155B2 (fr)
EP (1) EP2681218A1 (fr)
JP (1) JP5543039B2 (fr)
KR (1) KR101548443B1 (fr)
CN (1) CN103391941A (fr)
AP (1) AP2013007070A0 (fr)
AR (1) AR085304A1 (fr)
AU (1) AU2012221828C1 (fr)
BR (1) BR112013021366A2 (fr)
CA (1) CA2825699A1 (fr)
CL (1) CL2013002125A1 (fr)
CO (1) CO6751271A2 (fr)
CR (1) CR20130371A (fr)
CU (1) CU20130107A7 (fr)
DO (1) DOP2013000194A (fr)
EA (1) EA022586B1 (fr)
EC (1) ECSP13012892A (fr)
GT (1) GT201300206A (fr)
IL (1) IL227716A0 (fr)
MA (1) MA34922B1 (fr)
MX (1) MX2013009684A (fr)
NI (1) NI201300071A (fr)
PE (1) PE20140236A1 (fr)
PH (1) PH12013501556A1 (fr)
SG (1) SG192576A1 (fr)
TN (1) TN2013000349A1 (fr)
TW (1) TWI469983B (fr)
UA (1) UA106692C2 (fr)
UY (1) UY33916A (fr)
WO (1) WO2012114222A1 (fr)
ZA (1) ZA201306348B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2013007070A0 (en) * 2011-02-23 2013-08-31 Pfizer Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
NZ712949A (en) * 2013-05-02 2017-04-28 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
WO2015096651A1 (fr) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Composés pyrimidone carboxamide utilisés en tant qu'inhibiteurs de pde2
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
JP6626449B2 (ja) * 2014-04-23 2019-12-25 ダート・ニューロサイエンス・（ケイマン）・リミテッド ＰＤＥ２阻害剤としての置換［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−７−イル化合物
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學（開曼）有限責任公司 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物
HK1243936A1 (zh) 2014-12-06 2018-07-27 Intra-Cellular Therapies, Inc. 有机化合物
HK1243935A1 (zh) 2014-12-06 2018-07-27 Intra-Cellular Therapies, Inc. 有机化合物
CN104525240A (zh) * 2014-12-10 2015-04-22 河北工业大学 硝酸铁作为催化剂在苯与羟胺盐反应一步法制苯胺反应中的应用方法
WO2016103097A1 (fr) 2014-12-22 2016-06-30 Pfizer Inc. Antagonistes de récepteur ep3 de prostaglandine
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
WO2016145614A1 (fr) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Composés de triazolyl pyrimidinone en tant qu'inhibiteurs de pde2
WO2016154081A1 (fr) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Composés pyrazolyle pyrimidinone utilisés en tant qu'inhibiteurs de pde2
WO2016179059A1 (fr) 2015-05-05 2016-11-10 Merck Sharp & Dohme Corp. Composés d'hétéroaryl-pyrimidinone en tant qu'inhibiteurs de pde2
WO2016183741A1 (fr) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Composés de pyrimidinone amide en tant qu'inhibiteurs de pde2
WO2016191935A1 (fr) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. Composés 6-alkyle dihydropyrazolopyrimidinone utilisés en tant qu'inhibiteurs de pde2
WO2016192083A1 (fr) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Composés dihydropyrazolopyrimidinone utilisés en tant qu'en tant qu'inhibiteurs de pde2
EP3313852B1 (fr) 2015-06-25 2021-01-20 Merck Sharp & Dohme Corp. Composés bicycliques pyrazolo/imidazolo substitués en tant qu'inhibiteurs de pde2
WO2017004134A1 (fr) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Inhibiteurs d'irak et leurs utilisations
WO2017000276A1 (fr) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Composés hétérocycliques bicycliques utilisés en tant qu'inhibiteurs de pde2
WO2017000277A1 (fr) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclo-composés de triazole substitués utilisés en tant qu'inhibiteurs de pde2
HK1256751A1 (zh) 2015-11-02 2019-10-04 Janssen Pharmaceutica Nv [1，2，4]三唑并[1，5-a]嘧啶-7-基化合物
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
WO2018065288A1 (fr) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft Dérivés de 2-[2-phényl-1-(sulfonylméthyl)vinyl]-imidazo[4,5-b]pyridine et composés apparentés utilisés comme pesticides en protection des plantes
CN109937202B (zh) 2016-11-02 2022-12-30 詹森药业有限公司 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物
MA46690A (fr) 2016-11-02 2019-09-11 Janssen Pharmaceutica Nv Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
MY193511A (en) 2016-11-02 2022-10-17 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
EP3568395A1 (fr) 2017-01-10 2019-11-20 Bayer Aktiengesellschaft Dérivés hétérocycliques utilisés comme pesticides
US11058115B2 (en) 2017-01-10 2021-07-13 Bayer Aktiengesellschaft Heterocycle derivatives as pesticides
EP3713572B1 (fr) 2017-11-23 2025-07-30 Oslo University Hospital HF Traitement de la tachycardie
CN108640923A (zh) * 2018-07-09 2018-10-12 湖南天地恒制药有限公司 一种托法替布关键中间体的制备方法
EP3870300B1 (fr) * 2018-10-23 2024-07-10 Intra-Cellular Therapies, Inc. Composés de imidazo[1,5-a]pyrazine comme inhibiteurs de pde2
US11492362B1 (en) 2022-02-17 2022-11-08 King Abdulaziz University Pyridine derivatives for the treatment of hyperproliferative diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012113A1 (fr) * 1991-12-17 1993-06-24 The Upjohn Company 3-SUBSTITUE IMIDAZO (1,5-a) ET IMIDAZO (1,5-a)-TRIAZOLO (1,5-c) QUINOXALINES ET QUINAZOLINES AGISSANT SUR LE SYSTEME NERVEUX CENTRAL (SNC)
YU59100A (sh) * 1999-10-11 2003-10-31 Pfizer Inc. Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
WO2005041957A1 (fr) * 2003-10-29 2005-05-12 Pfizer Products Inc. Derives d'oxindole et leur utilisation comme inhibiteurs de la phosphodiesterase de type 2
DE602005014964D1 (de) 2004-04-02 2009-07-30 Osi Pharm Inc Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
TW200613306A (en) * 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
EP1812439B2 (fr) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
WO2006072612A2 (fr) * 2005-01-05 2006-07-13 Nycomed Gmbh Triazolophthalazines
BRPI0518508A2 (pt) 2005-01-07 2008-11-25 Pfizer Prod Inc compostos de quinolina heteroaromÁticos e seu uso como inibidores de pde10
PT2385053E (pt) 2005-11-17 2013-12-17 Osi Pharm Inc Intermediários para a preparação de compostos bicíclicos condensados como inibidores mtor
US7659274B2 (en) 2006-01-25 2010-02-09 Osi Pharmaceuticals, Inc. Unsaturated mTOR inhibitors
WO2007106503A2 (fr) 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Traitement combiné avec un inhibiteur de kinase egfr et un agent sensibilisant les cellules tumorales aux effets des inhibiteurs de kinase egfr
EP2526934B1 (fr) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibiteurs de la tyrosine kinase de bruton
JP2010532756A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
US7683575B2 (en) 2007-07-18 2010-03-23 Tesla Motors, Inc. Method and apparatus for identifying and disconnecting short-circuited battery cells within a battery pack
CA2716924A1 (fr) 2008-03-19 2009-09-24 Osi Pharmaceuticals, Inc. Formes de sel inhibiteur de mtor
EP2283020B8 (fr) 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Imidazopyrazines et imidazotriazines substituées
US20120108812A1 (en) 2009-07-09 2012-05-03 Osi Pharmaceuticals ,Inc. Process for substituted 3-amino-5-oxo-4,5-dihydro-[1,2,4]triazines
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
AP2013007070A0 (en) * 2011-02-23 2013-08-31 Pfizer Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders

Also Published As

Publication number Publication date
EA201390971A1 (ru) 2014-02-28
KR20130132612A (ko) 2013-12-04
NZ613373A (en) 2015-04-24
ZA201306348B (en) 2014-04-30
DOP2013000194A (es) 2014-01-31
WO2012114222A1 (fr) 2012-08-30
TWI469983B (zh) 2015-01-21
CL2013002125A1 (es) 2013-12-20
NI201300071A (es) 2014-02-12
PH12013501556A1 (en) 2017-10-25
TW201247673A (en) 2012-12-01
MA34922B1 (fr) 2014-02-01
TN2013000349A1 (fr) 2015-01-20
MX2013009684A (es) 2013-10-28
EP2681218A1 (fr) 2014-01-08
SG192576A1 (en) 2013-09-30
US20140066622A1 (en) 2014-03-06
US20120214791A1 (en) 2012-08-23
KR101548443B1 (ko) 2015-08-28
CA2825699A1 (fr) 2012-08-30
CN103391941A (zh) 2013-11-13
JP2014506589A (ja) 2014-03-17
EA022586B1 (ru) 2016-01-29
CR20130371A (es) 2013-09-18
ECSP13012892A (es) 2013-10-31
GT201300206A (es) 2015-02-19
CO6751271A2 (es) 2013-09-16
UA106692C2 (uk) 2014-09-25
AR085304A1 (es) 2013-09-18
JP5543039B2 (ja) 2014-07-09
IL227716A0 (en) 2013-09-30
AU2012221828B2 (en) 2015-05-28
US8598155B2 (en) 2013-12-03
AU2012221828C1 (en) 2015-10-01
CU20130107A7 (es) 2013-09-27
UY33916A (es) 2012-09-28
US9200000B2 (en) 2015-12-01
PE20140236A1 (es) 2014-03-14
BR112013021366A2 (pt) 2016-09-13

Similar Documents

Publication Publication Date Title
ZA201306348B (en) Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders
HUE037950T2 (hu) Heterobicikloszubsztituált [1,2,4]triazolo[1,5-C]kinazolin-5-amin vegyületek, amelyek alkalmasak központi idegrendszeri zavarok kezelésére vagy megelõzésére
IL228681A0 (en) 8-Ethyl-6(aryl)pyrido(3,2-d)pyrimidine-7(8h) - Potencies for the treatment of nervous system disorders and cancer
GB2503852B (en) Compounds for the treatment of neuropsychiatric disorders
ZA201202688B (en) 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
ZA201306038B (en) New compositions for treating neurological disorders
IL235659A (en) History 3, 4 - Dihydro-h2 - Pyrido [1, 2 - a] Pyrazine – 1, 6 - Transformed deion used to treat (among other things) Alzheimer's disease
ZA201501677B (en) Mglu2/3 antagonists for the treatment of autistic disorders
SMT201700531T1 (it) Derivati estrogeni per uso nel trattamento di disordini neurologici
HRP20181950T1 (hr) Samidorfan (alks 33) u kombinaciji s buprenorfinom za liječenje depresivnih poremećaja
SI2906209T1 (sl) D-metadon za zdravljenje psihiatričnih simptomov
PL2726470T3 (pl) Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych
IL238415B (en) Compounds for the treatment or prevention of diseases or disorders associated with dysregulation of eif4e
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
PL2691103T3 (pl) Metoda leczenia zaburzeń skóry
IL244619A0 (en) Pyrido[3-b,4]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
ZA201400967B (en) A method for predicting clinical benefit in the treatment of neurodevelopmental,neurological or neuropsychiatric disorders
PL395469A1 (pl) Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
HU0900722D0 (en) Compounds for the treatment of neurological disorders
IL228973A (en) Oxymetazoline for the treatment of rectal disorders
HK1194734A (en) 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8h)-ones for the treatment of nervous system disorders and cancer
EP2970118A4 (fr) Composés pour le traitement de troubles neurologiques